Mirum Pharmaceuticals, Inc.
Health
Performance
4.3
Risk
Sell
Buy
Curious about the Scores? Learn more.

Mirum Pharmaceuticals, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

17.07.2026
Risk creeping up. Stability not bulletproof anymore.
01.07.2026
Losing steam. Solid pieces remain, but cracks are showing.
12.12.2025
Outperforming hard. Momentum locked in.
MIRM
Mirum Pharmaceuticals, Inc.
116.56
-0.06%
4.3
Sell
Buy
Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Mirum Pharmaceuticals, Inc. do? Business model and key facts

Get the full picture of Mirum Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.

Mirum Pharmaceuticals, Inc. Profile

Sector: Healthcare

Industry: Biotechnology

Employees (FY): 418

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.

shop
Company facts
Christopher Peetz
CEO
418
Employees worldwide
shop
Performance
124.49%
Last 12 months
622.55%
Last 5 years
shop
Growth
$521.31M
Revenue year
$-23,363,000
Net income
shop
Valuation
$5.97B
Market Cap
-168.06
Price/Earnings Ratio

Stocks related to Mirum Pharmaceuticals, Inc.

Selected based on industry alignment and relative market positioning.

LGND
Ligand Pharmaceuticals Incorporated
300.98
+2.38%
5.0
Sell
Buy
Ligand Pharmaceuticals Incorporated
PTCT
PTC Therapeutics, Inc.
78.53
+0.67%
4.8
Sell
Buy
PTC Therapeutics, Inc.
ACLX
Arcellx, Inc.
115.07
+0.02%
4.9
Sell
Buy
Arcellx, Inc.
TVTX
Travere Therapeutics, Inc.
56.22
+1.34%
6.8
Sell
Buy
Travere Therapeutics, Inc.
APLS
Apellis Pharmaceuticals, Inc.
41.03
+0.00%
6.2
Sell
Buy
Apellis Pharmaceuticals, Inc.

Events and news impacting Mirum Pharmaceuticals, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

Mirum Pharmaceuticals, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.